Look for us at the 37th Annual J.P. Morgan Healthcare Conference taking place January 7-10, 2019 at the Westin St. Francis in San Francisco, CA.

About Scioto

OVERVIEW

Scioto is a preclinical stage company developing innovative therapies devoted to having a transformative impact on the delivery of microbiome therapeutics.

The Scioto Platform has the potential to enhance efficacy wherever live bacterial therapeutics are used such as diabetes, neurological disorders, gastrointestinal health, alternatives to in-feed antibiotics (Livestock) and others.

Our Research

Our Focus

By enabling colonization in the gut we believe that this novel technology will revolutionize live bacterial therapeutic interventions for other pathological states where there is erosion of the mucosal barrier.

Erosion of the physical mucus barrier leads to breaches and penetration of toxins, proteins and microbiota to enterocytes of the intestine.  The result is collectively termed “leaky gut” and often associated with low levels of chronic GI and systemic inflammation.  Thus, our technology will serve several unmet medical needs when applied as an intervention to fortify the mucosal barrier in states where breaches are documented.

Research and Development